Adam Cohen, MD, is currently serving as a Director of Myeloma Immunotherapy and Associate Professor of Medicine at the Abraham Cancer Center of the University of Pennsylvania, Philadelphia, PA. Dr Cohen is also a member of ASH, ASCO, AACR and the International Myeloma Society, as well as being a reviewer for a number of peer-reviewed journals.
Dr Cohen received his medical from the University of Pennsylvania, Philadelphia, PA, where he also completed his residency. He then went on to complete a fellowship at the Memorial Sloan Kettering Cancer Center, New York City, NY. Dr Cohen received board certification in medical oncology in 2005 and in hematology in 2011.
Speaking on transplantation therapies for myeloma and Waldenström macroglobulinemia
Dr Cohen specializes in adult stem cell collection for transplantation and the treatment of multiple myeloma and Waldenström macroglobulinemia. Dr Cohen is currently involved in a number of leading clinical trials investigating immunotherapies for the treatment of relapsed/refractory multiple myeloma, with a particular focus on chimeric antigen receptor (CAR) T-cell therapies and antibody therapies.